Weekly Digests



Combination ICB is greater than the sum of its parts

November 13, 2019

Anti-PD-1 and anti-CTLA-4 work through distinct mechanisms, and evidence from preclinical and early clinical trials has shown that these two checkpoint blockade therapies can be even more powerful when used in combination. To determine exactly how this combination works, Wei et al. set out to uncover whether the effects of combining anti-CTLA-4 and...

A little help from CD4+ T cells enables immunotherapy success

November 6, 2019

Aiming to understand the requirements for successful immunotherapy outcome, Alspach et al. explored the role of CD4+ T cells in antitumor response and found that expression of MHC-II neoantigens in the tumor, activation of CD4+ T cells, and CD4+ T cell help for CD8+ T cell priming and maturation were critical for response...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.